CRTX Financial Facts
Net income (loss): 9.58MNet income (loss) per share, diluted: 0.31
See Full Income Statement
Accounts payable: 7.53M
Additional paid-in capital: 170.24M
See Full Balance Sheet
Cornerstone Therapeutics Inc. (CRTX) Earnings
|
Expand Research on CRTX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -68.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +5.9% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/4/10  |
 |
Q310 | $0.15 | $0.04 | +$0.11 | N/A | N/A | N/A |  | | Details |
| 3/3/11 | |
Q410 | $0.20 | $0.12 | +$0.08 | $32.48M | $28.75M | N/A | | | Details |
| 5/12/11 |
|
Q111 | $0.17 | $0.15 | +$0.02 | $29.98M | $29.63M | N/A | | | Details |
| 8/4/11 |
|
Q211 | $0.11 | $0.06 | +$0.05 | $28.04M | $25.71M | N/A | | | Details |
| 11/3/11 |
|
Q311 | $0.13 | $0.14 | -$0.01 | $25.18M | $28.39M | N/A | | | Details |
| 3/8/12 | Q411 | -$0.06 | $0.09 | -$0.15 | $18.21M | $24.58M | N/A | | | Details | |
| 5/15/12 |
Q112 | $0.05 | $0.10 | -$0.05 | $22.2M | $20M | N/A | | | Details | |
| 8/9/12 | Q212 | -$0.17 | -$0.02 | -$0.15 | $21.47M | $18.84M | N/A | | | Details |
